Skip to main content
MedPathMedPath Home
Clinical Trials/NL-OMON46751
NL-OMON46751
Completed
Phase 2

Pharmacokinetics of fosfomycin: a study in patients with prolonged treatment for urinary tract infection - Pharmacokinetics of fosfomycin in prolonged treatment

HagaZiekenhuis0 sites12 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditionsbladder infectionUrinary tract infection1000401810046590

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
bladder infection
Sponsor
HagaZiekenhuis
Enrollment
12
Status
Completed
Last Updated
2 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
January 1, 2020
Last Updated
2 years ago
Study Type
Observational invasive

Investigators

Eligibility Criteria

Inclusion Criteria

  • •1\. Treatment of UTI with oral fosfomycin 3 gram every 3rd day for 14 days or longer as indicated by attending physician
  • •2\. Adults aged \*18 years

Exclusion Criteria

  • •1\. Proven allergy for fosfomycin
  • •2\. Pregnancy or breastfeeding
  • •3\. Usage of metoclopramide
  • •4\. Renal insufficiency defined as an estimated GFR \<30 ml/minute calculated by MDRD method
  • •5\. Active malignancy

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting
Phase 1
Fosfomycin concentrations in blood in persons with prolonged treatment with fosfomyci
EUCTR2018-000616-25-NL15
Recruiting
Phase 3
Evaluation of the Effect of Oral fosfomycin Addition on Treatment of Patients with Klebsiella pneumoniae Carbapnemase Infections with Colisti
IRCT20191104045328N1Arak University of Medical Sciences62
Active, not recruiting
Phase 1
Efficacy and safety of intravenous fosfomycin in prosthetic joint infection (PJI)Prosthetic joint infection of knee, hip or shoulderTherapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]
EUCTR2016-002673-35-DEPRO-IMPLANT Foundation226
Recruiting
Phase 3
Efficacy of oral fosfomycin as a step down therapy after treatment for upper urinary tract infection caused by extended&#45;spectrum b&#45;lactamase&#45;producing Escherichia colipper urinary tract infectionESBL&#45producing E. coliUpper urinary tract infectionAcute pyelonephritisOral fosfomycinStep down therapySwitching therapy
TCTR20171021001Research department&#44; Faculty of Medicine Siriraj Hospital&#44; Mahidol University140
Not yet recruiting
Phase 4
Intravenous Fosfomycin in hospitalized patients with complicated urinary tract infections due to Third-generation cephalosporinresistant Enterobacterales
2024-516591-15-00Azienda Ospedaliero Universitaria Di Modena548